avxs News

• Recent acquisitions and clinical trial stumbles show the high-risk, high-return nature of biotech IPOs. Betting on a biotech buyout... The...read more

The 21 IPOs this year that have raised raised over $100 million have delivered investors an average return of 32%, including a first-day pop of 14% and an additional 14% in the aftermarket. Most notably, only one IPO in this group currently trades below issue, biotech Hutchison China MediTech (HCM). Top-performers are fast-growing tech companies...read more

The US IPO market in the 1Q16 hit its lowest levels since the depths of the financial crisis in 2008/2009. Not a single deal priced outside of the health care sector, where eight deals managed to raise $0.7 billion thanks to substantial buying by their existing shareholders. The resulting low tradable float also helped to prop up performance, and IPOs averaged a return of 25%, even...read more

The IPO market was poised to raise $1.4 billion from four IPOs this past week, but instead two biotechs raised $145 million. A substantial portion of those proceeds came from insiders, and both biotechs broke issue with an average loss of 17%. With markets off and volatility up; it is more difficult for issuers and IPO buyers to find agreeable price. So far, ...read more